June 5 2019 web conference presentation
05/06/2019 – AB Science web conference – Part 2
Summary of the webconference held on June 4, 2019
04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019
June 4 2019 web conference presentation
04/06/2019 – AB Science web conference presentation (Part 1)
Web conference on June 4 and 5, 2019
30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET
Lifting of the ANSM clinical hold
28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.
Annual financial results as of 31 December, 2018
30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.
Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.
Update on the restructuring of the AB Science clinical development department in 2018
19/12/2018 – AB Science provides the main achievements of this restructuring.
Patients
The following studies are currently recruiting patients Masitinib in prostate cancer The following studies will start recruitment in 2019: Masitinib in Amyotrophic Lateral Sclerosis Masitinib in indolent systemic severe mastocytosis AB8939 in acute myeloid leukemia Patients If you wish to participate in this study, please contact us at the following address:clinical@ab-science.com